Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Thomas Jefferson University
Medical College of Wisconsin
Brown University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Weill Medical College of Cornell University
Thomas Jefferson University
Masonic Cancer Center, University of Minnesota
Thomas Jefferson University
UNC Lineberger Comprehensive Cancer Center
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Pfizer
SCRI Development Innovations, LLC
Rutgers, The State University of New Jersey
Karyopharm Therapeutics Inc
Amgen
Genenta Science
University of Michigan Rogel Cancer Center
National Institutes of Health Clinical Center (CC)
Northside Hospital, Inc.
National Cancer Institute (NCI)
Kiadis Pharma
National Cancer Institute (NCI)
Dartmouth-Hitchcock Medical Center
M.D. Anderson Cancer Center
Novartis
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
University of Arizona
National Cancer Institute (NCI)
Incyte Corporation
Barbara Ann Karmanos Cancer Institute
National Institutes of Health Clinical Center (CC)
Stanford University
AbbVie
Masonic Cancer Center, University of Minnesota
Fred Hutchinson Cancer Center